Johnson & Johnson 8-K
PositiveEarningsGuidance raisedRestructuring
Oncology and TREMFYA drive Innovative Medicine growth despite STELARA declines; strong operations lift sales and adjusted EPS guidance.
Filed 2026-07-15 07:49 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Q2 2026 results with raised FY2026 guidance. Sales grew 6.6% to $25.3B, while diluted EPS was $2.27; adjusted diluted EPS rose 4.7% to $2.90. J&J raised its outlook for sales and adjusted EPS, citing strong operating performance.
Key Figures
| Metric | Q2 2026 | Q2 2025 | Y/Y |
|---|---|---|---|
| Sales | $25.3B | $23.7B | 6.6% |
| Net earnings | $5.53B | $5.54B | (0.1)% |
| Diluted EPS | $2.27 | $2.29 | (0.9)% |
| Adjusted net earnings (non-GAAP) | $7.08B | $6.70B | 5.7% |
| Adjusted diluted EPS (non-GAAP) | $2.90 | $2.77 | 4.7% |
- Sales growth was 5.6% operationally and 5.7% adjusted operationally. Innovative Medicine sales grew 6.8% operationally, led by oncology, TREMFYA and neuroscience products; STELARA’s decline reduced growth by approximately 760 bp. MedTech grew 3.6%, led by wound closure, biosurgery, electrophysiology, Shockwave, contact lenses and trauma.
- A new supply-chain restructuring, primarily in Innovative Medicine, is expected to cost $650M–$750M and be substantially complete by FY2029; $200M of expense, primarily asset impairments, was recorded in Q2.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Adjusted operational sales (non-GAAP) | FY2026 | 6.2%–6.8%; midpoint 6.5% | 5.6%–6.6%; midpoint 6.1% | Raised |
| Operational sales (non-GAAP) | FY2026 | $100.3B–$100.9B; midpoint $100.6B; growth 6.5%–7.1%, midpoint 6.8% | $99.7B–$100.7B; midpoint $100.2B; growth 5.9%–6.9%, midpoint 6.4% | Raised |
| Estimated reported sales | FY2026 | $100.8B–$101.4B; midpoint $101.1B; growth 7.0%–7.6%, midpoint 7.3% | $100.3B–$101.3B; midpoint $100.8B; growth 6.5%–7.5%, midpoint 7.0% | Raised |
| Adjusted operational diluted EPS (non-GAAP) | FY2026 | $11.5–$11.65; midpoint $11.58; growth 6.6%–8.0%, midpoint 7.3% | $11.3–$11.5; midpoint $11.40; growth 4.7%–6.7%, midpoint 5.7% | Raised |
| Adjusted diluted EPS (non-GAAP) | FY2026 | $11.6–$11.75; midpoint $11.68; growth 7.5%–8.9%, midpoint 8.2% | $11.45–$11.65; midpoint $11.55; growth 6.1%–8.1%, midpoint 7.1% | Raised |
J&J does not provide forward-looking GAAP financial measures, citing difficulty predicting legal proceedings, unusual gains and losses, acquisition-related expenses and purchase-accounting adjustments. Additional modeling considerations were to be provided on the webcast.
Investor Takeaways
- Watch FY2026 reported sales against the raised $100.8B–$101.4B range and adjusted diluted EPS against $11.60–$11.75.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3